Immunology: Getting a handle on HIV control and more of the latest research news from Nature

Clues to how a rare group of patients can resist infection by HIV are reported in a paper this week in Nature Immunology. So-called ‘elite controllers’ are able to retain normal immune function and undetectable levels of HIV infection despite regular exposure to the virus.

NATURE AND THE NATURE RESEARCH JOURNALS PRESS RELEASE

This press release contains:

· Summaries of newsworthy papers:

Immunology: Getting a handle on HIV control
Nature: Characterising breast cancer features and response to therapy
Genetics: Variants associated with migraine
Geoscience: Submarine eruption cycle
Chemical Biology: Inhibiting caspase-6 by stabilizing an inactive form
Medicine: Clue to leukemia growth and resistance to therapy
Nature: Predicting adverse drug reactions
Medicine: Digitally mining tumors for therapy response markers
Chemical Biology: Metabolic inhibitor strategy strikes again
Methods: Assessing microbial diversity
And finally…Nature: Big fish families don’t like small ponds

PDFs of all the papers mentioned on this release can be found in the relevant journal’s section of http://press.nature.com. Press contacts for the Nature journals are listed at the end of this release.

[1] Immunology: Getting a handle on HIV control
DOI: 10.1038/ni.2342

Clues to how a rare group of patients can resist infection by HIV are reported in a paper this week in Nature Immunology. So-called ‘elite controllers’ are able to retain normal immune function and undetectable levels of HIV infection despite regular exposure to the virus.

Suspecting that characteristics of the white blood cell cytotoxic T lymphocyte (CTL) response was responsible for this remarkable immune control, Bruce Walker and colleagues compared the CTL responses of elite controllers and susceptible individuals across numerous highly defined and consistent parameters. Only two clear differences could be seen; the first was that the CTLs of elite controllers had more efficient killing of infected cells, and the second was that these same CTLs could better tackle HIV mutants which are normally able to evade immune responses. These properties appeared to depend on the make-up of the CTL populations found in elite controllers. Specifically, the T cell receptor that the CTLs use to detect virus contained unique features enabling them to kill a wide range of infected target cells.

Understanding how elite controllers keep HIV in check is of critical importance for T cell vaccine design and therapeutic strategies.

Author contact:
Bruce Walker (Massachusetts General Hospital, Charlestown, MA, USA)
Tel: +1 617 724 8332; E-mail: [email protected]

[2] Nature: Characterising breast cancer features and response to therapy
DOI: 10.1038/nature11143

Whole-genome sequencing provides insights into mutations that correlate with specific clinical features and responses to treatment in oestrogen receptor positive (ER+) breast cancer are provided by a study in Nature this week. In particular, the association between certain mutations and response of ER+ breast cancer to treatment with aromatase inhibitors is characterised.

ER+ breast tumours are sensitive the hormone oestrogen, which stimulates tumour growth; aromatase inhibitors help block the growth of these tumours by lowering the amount of oestrogen in the body. Elaine Mardis and colleagues performed whole-genome sequencing on biopsies from ER+ breast cancer patients enrolled in a clinical trial investigating aromatase inhibitor therapy. They identify a number of disease-linked mutations that specifically correlate with tumour cells abnormalities, how quickly the tumour is likely to grow and spread, and response to treatment. Such information could be used to determine which patients will benefit from aromatase inhibitor therapy.

The authors’ findings suggest that an approach in which patient management is dictated by genomic data derived from unbiased sequencing is feasible and promising for individualizing therapeutic decisions.

Author contact:
Elaine Mardis (Washington University, St. Louis, MO, USA)
Tel: +1 314 286 1805; E-mail: [email protected]

[3] Genetics: Variants associated with migraine
DOI: 10.1038/ng.2307

Genetic variants associated with migraine without aura are reported in a study this week in Nature Genetics.

Migraine without aura is the most common form of migraine, a disabling episodic neurovascular brain disorder affecting 12% of the general population. Migraine with neurological aura symptoms occurs in approximately one-third of cases.

Arn van den Maagdenberg, Aarno Palotie, Tobias Freilinger and colleagues report a genome-wide association study in 2,326 clinic-based German and Dutch individuals with migraine without aura and 4,580 population-matched controls. They identify two genomic regions significantly associated with migraine without aura. The authors also replicate associations at two loci previously associated with migraine in general (not specified for migraine subtype), suggesting a shared genetic basis.

Author contact:
Arn van den Maagdenberg (Leiden University Medical Centre, Netherlands)
Tel: +31 71 5269460; E-mail: [email protected]

[4], [5] & [6] Geoscience: Submarine eruption cycle
DOI: 10.1038/ngeo1464
DOI: 10.1038/ngeo1490
DOI: 10.1038/ngeo1496

Detailed observations of an underwater volcano reveal a gradual rise of the sea bed in the run-up to eruption, accompanied by a swarm of earthquakes just before the eruption, and followed by a rapid drop of the sea bed at the time of the eruption. This finding is reported in three complementary studies published online this week in Nature Geoscience. Submarine volcanism — the vast majority of volcanism on Earth — has had little scientific attention, making the new observations of Axial Seamount volcano in the Pacific Ocean particularly valuable.

William Chadwick Jr, Robert Dziak, David Caress and colleagues surveyed Axial Seamount before and after an eruption in April 2011. They used a robotic submersible to analyse the seafloor topography, pressure sensors to measure inflation and deflation of the sea bed, and hydrophones to record waterborne signals of small earthquakes caused by magma moving in the Earth’s crust. They record gradual inflation of the sea bed in the years leading up to the eruption, as the magma reservoir beneath the volcano gradually filled. Thereafter, the sea bed deflated as the magma intruded into the oceanic crust and erupted as lava flows on the sea floor. In the two hours before the eruption, a swarm of intense earthquakes occurred.

In an accompanying News and Views article, Neil Mitchell writes that the studies "highlight the pulsed nature and rapid growth and collapse of submarine volcanoes during eruptions."

Author contacts:
William Chadwick Jr (Oregon State University, Newport, OR, USA) Author paper [4]
Tel: +1 541 867 0179; E-mail: [email protected]

Robert Dziak (Oregon State University, Newport, OR, USA) Author paper [5]
Tel: +1 541 867 0175; E-mail: [email protected]

David Caress (Monterey Bay Aquarium Research Institute, Moss Landing, CA, USA) Author paper [6]
Tel: +1 831 775 1775; E-mail: [email protected]

Neil Mitchell (University of Manchester, UK) N&V author
Tel: +44 161 2750779; E-mail: [email protected]

[7] Chemical Biology: Inhibiting caspase-6 by stabilizing an inactive form
DOI: 10.1038/nchembio.967

A peptide that inactivates caspase-6, a cell death promoting enzyme important in Alzheimer’s disease, is reported this week in Nature Chemical Biology.

Caspases are enzymes that mediate cell death and inflammatory responses. Although many caspase inhibitors have been reported, there are currently no drugs available that target these enzymes. Most drug discovery approaches aimed at this target class have produced compounds that inhibit the active site of the enzymes through an irreversible modification. Translation of this approach to the clinic has been hindered because long-term exposure to these compounds is associated with liver toxicity, thus new approaches to inhibit these enzymes are needed.

Rami Hannoush and colleagues report on a peptide called pep419 that inhibits caspase-6 by a new mechanism, providing a potential new strategy to inhibit this enzyme. Upon activation in cells, caspase-6 is processed from an inactive to an active form. Pep419 binds to and stabilizes an inactive form of caspase-6, selectively inhibiting caspase-6 activity in neuronal cells. These results indicate that recapitulating the activity of pep419 could be an effective drug discovery strategy for targeting caspase-6.

Author contact:
Rami Hannoush (Genentech, South San Francisco, CA, USA)
Tel +1 650 467 3696; E-mail [email protected]

[8] Medicine: Clue to leukemia growth and resistance to therapy
DOI: 10.1038/nm.2819

Leukemic cells can feed themselves through increased secretion of hepatocyte growth factor (HGF), which then activates its receptor, MET, to promote growth. This autocrine loop allows the leukemic cells to sidestep therapeutic inhibition of MET, shows a report published online in this week’s Nature Medicine.

Thomas Look and colleagues use a type of genomic screen and identify abnormal HGF expression as a crucial factor for development of a class of acute leukemia in leukemia cell lines and clinical samples. The team show that treatment with MET inhibitors resulted in drug resistance owing to increased HGF expression to compensate for MET blockade.

The findings illustrate the potential relevance of considering adaptive responses by tumor cells when designing targeted therapies for cancer.

Author contact:
Tom Look (Dana-Farber Cancer Institute, Boston, MA, USA)
Tel: +1 617 632 5826; E-mail: [email protected]

[9] Nature: Predicting adverse drug reactions
DOI: 10.1038/nature11159

A large-scale, prospective evaluation of the activity of 656 clinically used drugs against 73 protein targets that may be associated with adverse reactions is reported in Nature this week. Of the 1,042 predictions that were tested, approximately half were confirmed.

Drugs frequently interact with more than one protein target, and there are hundreds of such proteins that are linked to the side effects of clinically used therapeutics. Brian Shoichet, Laszlo Urban and colleagues use a computational approach to predict such undesirable interactions. One of the new predictions suggested that the abdominal pain known to occur in some patients receiving the non-steroidal oestrogen chlorotrianisene was mediated through its newly discovered inhibition of cyclooxygenase-1, the protein target of non-steroidal anti-inflammatory drugs such as aspirin.

Because adverse drug reactions are the second most common reason why a potential drug fails in clinical trials, the authors of this study believe that their approach could be used to identify 'problematic' small molecules earlier in the drug development process, saving time and money that could be re-directed to more promising drug candidates.

Author contact:
Brian Shoichet (University of California, San Francisco, CA, USA)
Tel: +1 415 514 4126; E-mail: [email protected]

Laszlo Urban (Novartis Institutes for BioMedical Research, Boston, MA, USA)
Tel: +1 617 8717144; E-mail: [email protected]

[10] Medicine: Digitally mining tumors for therapy response markers
DOI: 10.1038/nm.2795

Lower amounts of an enzyme called DUSP4 are associated with resistance to neadjuvant chemotherapy—which is given before surgical tumor removal—and aggressive breast cancers, reports a paper published online this week in Nature Medicine. Further validation in clinical trials will confirm whether DUSP4 could be a potential marker of therapy outcome.

Neadjuvant chemotherapy, which is given before surgical tumor removal, can reduce the size of the tumor. But many patients do not have a complete response and show residual cancer after this treatment and an increased risk for metastatic disease.

Using digital DNA quantification in surgically-resected tumors after neo-adjuvant chemotherapy, Carlos Arteaga and colleagues show that the levels of DUSP4, a negative regulator of oncogenic signaling, are decreased in breast cancer patients with poor outcome and short survival. Activation of the oncogenic Ras-ERK pathway seems to be the result of decreased DUSP4, causing impaired cancer cell apoptosis.

The findings suggest that this signaling pathway may be targeted to improve the response to chemotherapy.

Author contact:
Carlos Arteaga (Vanderbilt University School of Medicine, Nashville, TN, USA)
Tel: +1 615 936 3524; E-mail: [email protected]

[11] Chemical Biology: Metabolic inhibitor strategy strikes again
DOI: 10.1038/nchembio.999

Cell-permeable inhibitors for new classes of enzymes are described in a paper published online this week in Nature Chemical Biology. These enzyme inhibitors have relevance for exploring the basic biology behind diseases by understanding development, cell trafficking, and host-pathogen interactions.

Finding enzyme inhibitors that can cross the cell membrane to act in cells remains a significant challenge, especially for inhibitors of carbohydrate processing enzymes that are often highly charged. The cellular enzymes that control carbohydrate metabolism are known to permit some non-natural molecules into normal metabolic pathways. In addition, medicinal chemists have long worked on ‘pro-drugs’, or molecules that are disguised in some way and then altered once inside the body or a cell to become active. Prior research had demonstrated that these two ideas could be combined to create a sugar analogue that is disguised to allow cell permeability, but then gets transformed in several steps into an activate inhibitor of a glycosyltransferase.

James Paulson and colleagues demonstrate that this same strategy can be used to create synthetic inhibitors of sialyltransferases and fucosyltransferases, enzymes that attach special sugar groups – sialic acids and fucoses, respectively – to a variety of biological targets. As there are currently no small molecule inhibitors of these enzymes that work in cells, these new compounds should provide immediate entry to further research into how carbohydrate structure is linked to important biological processes.

Author contact:
James Paulson (The Scripps Research Institute, La Jolla, CA, USA)
Tel: +1 858 784 9634; E-mail: [email protected]

[12] Methods: Assessing microbial diversity
DOI: 10.1038/nmeth.2066

A tool for rapidly and accurately determining the phylogenetic makeup of large microbial communities is reported online this week in Nature Methods. The work combines data from the Human Microbiome Project and MetaHIT (metagenomics of the human intestinal tract) for the largest metagenomic profile of the human gut to date.

Microorganisms play an important role in all natural environments and their influence on human health is coming under more and more scrutiny. To really understand their impact one needs to know the composition of microbial communities, an endeavor made possible by high throughput sequencing. But current computational methods to determine community profiles from sequence data are either too slow to deal with large datasets or cannot achieve accurate assignment at the species or genus level.

Curtis Huttenhower and colleagues solved these problems with a program that is both fast and highly accurate. MetaPhlAn (metagenomic phylogenetic analysis) can assign millions of short sequence reads to the correct taxon in minutes and also estimates their abundance. It achieves this speed and accuracy by mapping reads to a database of markers, each unequivocally assigning a read to its species, genus or higher taxonomic level.

Author contact:
Curtis Huttenhower (Harvard School of Public Health, Boston, MA, USA)
Tel: +1 617 432 4912; E-mail: [email protected]

Daniel D Haft (J. Craig Venter Institute, Rockville, MD, USA) N&V author
Tel: +1 301 795 7000; E-mail: [email protected]

[13] And finally…Nature: Big fish families don’t like small ponds
DOI: 10.1038/nature11144

Adaptive radiation ― the rapid evolution of diversity within animal or plant groups ― can be predicted when considering both environmental factors and species traits according to research in Nature this week. The article uncovers a combination of factors that can predict the diversification of African cichlids, a large, diverse family of fishes that provide a classic study system for adaptive radiation. It shows that adaptive radiation in these fish is more likely in deeper, older and sunnier lakes, and where species show high levels of sexual selection.

Cichlids in a large number of lakes across Africa provide many examples of diversification by adaptive radiation, but in around four times as many cases adaptive radiation has not occurred. Ole Seehausen and colleagues study 656 species in 46 lakes and identify the environmental features and characteristics intrinsic to the species that govern whether radiation occurs. Environmental features that encourage radiation include deep and old lakes, which may provides energy. These factors together with an association between differences in the appearances of male and female fishes and diversification, an indicator of sexual selection, best predict whether radiation will occur.

These results suggest that it is possible to predict adaptive radiation, but only when traits and environmental factors are jointly considered, the authors conclude.

Author contact:
Ole Seehausen (The University of Bern, Switzerland)
Tel: +41 31 6313131; E-mail: [email protected]

*************************************************************************************************

Items from other Nature journals to be published online at the same time and with the same embargo:

Nature (http://www.nature.com/nature)

[14] A tumour suppressor network relying on the polyamine–hypusine axis
DOI: 10.1038/nature11126

[15] SbsB structure and lattice reconstruction unveil Ca21 triggered S-layer assembly
DOI: 10.1038/nature11155

NATURE CELL BIOLOGY (http://www.nature.com/naturecellbiology)

16] miR-129-3p controls cilia assembly by regulating CP110 and actin dynamics
DOI: 10.1038/ncb2512

[17] The S. pombe cytokinesis NDR kinase Sid2 activates Fin1 NIMA kinase to control mitotic commitment through Pom1/Wee1
DOI: 10.1038/ncb2514

[18] The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r
DOI: 10.1038/ncb2521

NATURE CHEMISTRY (http://www.nature.com/nchem)

[19] Crystal structure of [delta]-Ru(bpy)2dppz2+ bound to mismatched DNA reveals side-by-side metalloinsertion and intercalation
DOI: 10.1038/nchem.1375

[20] An improved high-performance lithium–air battery
DOI: 10.1038/nchem.1376

[21] Non-Markovian polymer reaction kinetics
DOI: 10.1038/nchem.1378

[22] The synthesis, crystal structure and charge-transport properties of hexacene
DOI: 10.1038/nchem.1381

NATURE CLIMATE CHANGE (http://www.nature.com/nclimate)

[23] Human-induced global ocean warming on multidecadal timescales
DOI: 10.1038/nclimate1553

[24] The gigatonne gap in China’s carbon dioxide inventories
DOI: 10.1038/nclimate1560

[25] Soil-mediated effects of subambient to increased carbon dioxide on grassland productivity
DOI: 10.1038/nclimate1573

[26] Human drivers of national greenhouse-gas emissions
DOI: 10.1038/nclimate1506

NATURE GENETICS (http://www.nature.com/naturegenetics)

[27] Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial function and intracellular cholesterol trafficking and cause dystonia and deafness
DOI: 10.1038/ng.2325

[28] BAP1 loss defines a new class of renal cell carcinoma
DOI: 10.1038/ng.2323

[29] Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome
DOI: 10.1038/ng.2316

NATURE MATERIALS (http://www.nature.com/naturematerials)

[30] Extraordinarily complex crystal structure with mesoscopic patterning in barium at high pressure
DOI: 10.1038/nmat3342

[31] Al13Fe4 as a low-cost alternative for palladium in heterogeneous hydrogenation
DOI: 10.1038/nmat3347

Nature MEDICINE (http://www.nature.com/naturemedicine)

[32] Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects
DOI: 10.1038/nm.2834

NATURE METHODS (http://www.nature.com/nmeth)

[33] Rapid, accurate particle tracking by calculation of radial symmetry centers
DOI: 10.1038/nmeth.2071

[34] Elastic volume reconstruction from series of ultra-thin microscopy sections
DOI: 10.1038/nmeth.2072

NATURE NANOTECHNOLOGY (http://www.nature.com/nnano)

[35] Self-orienting nanocubes for the assembly of plasmonic nanojunctions
DOI:10.1038/nnano.2012.83

[36] Shear-stress sensitive lenticular vesicles for targeted drug delivery
DOI:10.1038/nnano.2012.84

Nature NEUROSCIENCE (http://www.nature.com/natureneuroscience)

[37] Calcium-channel number critically influences synaptic strength and plasticity at the active zone
DOI: 10.1038/nn.3129

[38] Autism spectrum disorder susceptibility gene TAOK2 affects basal dendrite formation in the neocortex
DOI: 10.1038/nn.3141

[39] Release probability of hippocampal glutamatergic axon terminals scales with the size of the active zone
DOI: 10.1038/nn.3137

Nature PHYSICS (http://www.nature.com/naturephysics)

[40] Experimental device-independent tests of classical and quantum dimensions
DOI: 10.1038/nphys2333

[41] Experimental estimation of the dimension of classical and quantum systems
DOI: 10.1038/nphys2334

Nature STRUCTURAL & MOLECULAR BIOLOGY (http://www.nature.com/natstructmolbiol)

[42] Structural dynamics of the aminoacylation and proofreading functional cycle of bacterial leucyl-tRNA synthetase
DOI: 10.1038/nsmb.2317

[43] Visualizing transient protein-folding intermediates by tryptophan-scanning mutagenesis
DOI: 10.1038/nsmb.2322

[44] The zinc-finger domains of PARP1 cooperate to recognise DNA strand-breaks
DOI: 10.1038/nsmb.2335

****************************************************************************************
GEOGRAPHICAL LISTING OF AUTHORS

The following list of places refers to the whereabouts of authors on the papers numbered in this release. The listing may be for an author's main affiliation, or for a place where they are working temporarily. Please see the PDF of the paper for full details.

AUSTRALIA
Brisbane: 3
Hobart: 23

BELGIUM
Brussels: 15, 18
Liege: 3

CANADA:
Burnaby: 1
Montreal: 14, 43

CHINA
Beijing: 24
Shanghai: 16
Shenyang: 24

CROATIA
Split:
Zagreb: 27

CZECH REPUBLIC
Olomouc: 41

FINLAND
Helsinki: 3
Tampere: 3, 27
Turku: 3

FRANCE
Grenoble: 42
Paris: 15, 18, 21

GERMANY
Berlin: 31
Cologne: 29
Dresden: 31, 34
Freiburg: 36, 39
Friedrichshafen: 29
Goettingen: 29
Heidelberg: 37
Juelich: 31
Kiel: 3
Lubeck: 27
Munich: 3, 31
Neuherberg: 3
Regensburg: 1, 29
Ulm: 3

HUNGARY
Budapest: 31, 39

INDIA
Delhi: 23, 27

IRELAND
Dublin: 32

ITALY
Rome: 20
Trento: 12

JAPAN
Ibaraki: 23
Sapporo: 39
Tokyo: 1

KOREA
Seoul: 20

LATVIA
Riga: 27

NETHERLANDS
Amsterdam: 27
Leiden: 3, 29
Nijmegen: 27
Rotterdam: 3, 8
Utrecht: 27

NORWAY
Oslo: 3
Trondheim: 3

PERU
Lima: 10

POLAND
Warsaw: 27

SPAIN
Barcelona: 3, 29, 41
Madrid: 29, 32
Seville: 40

SWEDEN
Stockholm: 27, 38, 40

SWITZERLAND
Basel: 9, 36
Bern: 13
Geneva: 36
Lausanne: 17
Kastanienbaum: 13
Zurich: 34

TURKEY
Izmir: 27

UNITED KINGDOM
Bristol: 41
Cambridge: 3, 18, 24
Edinburgh: 30
Leeds: 24
Little Chesterford: 28
London: 10, 11, 15
Manchester: 8, 17

UNITED STATES OF AMERICA

California
Davis: 31
Duarte: 8
La Jolla: 8, 11, 23, 35
Livermore: 23
Moss Landing: 6
Pasadena: 19
San Diego: 28
San Francisco: 2, 7, 9
Santa Barbara: 43
Santa Cruz: 2, 6
Stanford: 26

Georgia
Athens: 11

Idaho
Moscow: 13

Illinois
Chicago: 8
Urbana: 42

Maryland
Baltimore: 37, 38
Bethesda: 1, 8, 37
Chevy Chase: 1, 2
College Park: 24

Massachusetts
Boston: 1, 3, 8, 12
Cambridge: 9, 38

Michigan
East Lansing: 26
Grand Rapids: 8

Minnesota
Minneapolis: 18
Rochester: 2

Missouri
St Louis: 2

Nebraska
Lincoln: 25

New Jersey
Newark: 38

New York
Cold Spring Harbor: 14
Ithaca: 13
New York: 4, 14
Palisades: 5

North Carolina
Durham: 2, 25
Raleigh: 5

Ohio
Cincinnati: 2

Oregon
Eugene: 33
Newport: 4, 5, 6

Tennessee
Nashville: 10

Texas
Dallas: 2, 28
Houston: 2, 10
Laredo: 2
Temple: 25

Utah
Provo: 25

Virginia
Ashburn: 34

Washington
Pullman: 26
Seattle: 4, 5, 6

PRESS CONTACTS…

For media inquiries relating to embargo policy for all the Nature Research Journals:

Rachel Twinn (Nature London)
Tel: +44 20 7843 4658; E-mail: [email protected]

Neda Afsarmanesh (Nature New York)
Tel: +1 212 726 9231; E-mail: [email protected]

Eiji Matsuda (Nature Tokyo)
Tel: +81 3 3267 8751; E-mail: [email protected]

For media inquiries relating to editorial content/policy for the Nature Research Journals, please contact the journals individually:

Nature Biotechnology (New York)
Michael Francisco
Tel: +1 212 726 9288; E-mail: [email protected]

Nature Cell Biology (London)
Sowmya Swaminathan
Tel: +44 20 7843 4656; E-mail: [email protected]

Nature Chemical Biology (Boston)
Elissa Bolt
Tel: +1 617 475 9241, E-mail: [email protected]

Nature Chemistry (London)
Stuart Cantrill
Tel: +44 20 7014 4018; E-mail: [email protected]

Nature Climate Change (London)
Rory Howlett
Tel: +44 20 7014 4009; E-mail: [email protected]

Nature Genetics (New York)
Myles Axton
Tel: +1 212 726 9324; E-mail: [email protected]

Nature Geoscience (London)
Heike Langenberg
Tel: +44 20 7843 4042; E-mail: [email protected]

Nature Immunology (New York)
Laurie Dempsey
Tel: +1 212 726 9372; E-mail: [email protected]

Nature Materials (London)
Vincent Dusastre
Tel: +44 20 7843 4531; E-mail: [email protected]

Nature Medicine (New York)
Juan Carlos Lopez
Tel: +1 212 726 9325; E-mail: [email protected]

Nature Methods (New York)
Ray Parker
Tel: +1 212 726 9627; E-mail: [email protected]

Nature Nanotechnology (London)
Peter Rodgers
Tel: +44 20 7014 4019; Email: [email protected]

Nature Neuroscience (New York)
Kalyani Narasimhan
Tel: +1 212 726 9319; E-mail: [email protected]

Nature Photonics (Tokyo)
Oliver Graydon
Tel: +81 3 3267 8776; E-mail: [email protected]

Nature Physics (London)
Alison Wright
Tel: +44 20 7843 4555; E-mail: [email protected]

Nature Structural & Molecular Biology (New York)
Michelle Montoya
Tel: +1 212 726 9331; E-mail: [email protected]

About Nature Publishing Group (NPG):

Nature Publishing Group (NPG) is a publisher of high impact scientific and medical information in print and online. NPG publishes journals, online databases and services across the life, physical, chemical and applied sciences and clinical medicine.

Focusing on the needs of scientists, Nature (founded in 1869) is the leading weekly, international scientific journal. In addition, for this audience, NPG publishes a range of Nature research journals and Nature Reviews journals, plus a range of prestigious academic journals including society-owned publications. Online, nature.com provides over 5 million visitors per month with access to NPG publications and online databases and services, including Nature News and NatureJobs plus access to Nature Network and Nature Education’s Scitable.com.

Scientific American is at the heart of NPG’s newly-formed consumer media division, meeting the needs of the general public. Founded in 1845, Scientific American is the oldest continuously published magazine in the US and the leading authoritative publication for science in the general media. Together with scientificamerican.com and 15 local language editions around the world it reaches over 3 million consumers and scientists. Other titles include Scientific American Mind and Spektrum der Wissenschaft in Germany.

Throughout all its businesses NPG is dedicated to serving the scientific and medical communities and the wider scientifically interested general public. Part of Macmillan Publishers Limited, NPG is a global company with principal offices in London, New York and Tokyo, and offices in cities worldwide including Boston, Buenos Aires, Delhi, Hong Kong, Madrid, Barcelona, Munich, Heidelberg, Basingstoke, Melbourne, Paris, San Francisco, Seoul and Washington DC. For more information, please go to www.nature.com.

Published: 10 Jun 2012

Contact details:

The Macmillan Building, 4 Crinan Street
London
N1 9XW
United Kingdom

+44 20 7833 4000
Country: 
Journal:
News topics: 
Content type: 
Websites: 

http://press.nature.com Nature press site http://www.nature.com/ni/ Nature Immunology http://www.nature.com Nature http://www.nature.com/ng Nature Genetics http://www.nature.com/ngeo Nature Geoscience http://www.nature.com/nchembio/ Nature Chemical Biology http://www.nature.com/nm Nature Medicine

Reference: 

Nature and Nature Research Journals

Gut

Medicine